Skip to content

Efficacy and Safety of Sini Powder Combined with Xiaoxianxiong Decoction for Adolescent Depression with Liver Qi Stagnation and Phlegm-Heat Obstruction Syndrome: A Randomized Controlled Trial

Efficacy and Safety of Sini Powder Combined with Xiaoxianxiong Decoction for Adolescent Depression with Liver Qi Stagnation and Phlegm-Heat Obstruction Syndrome: A Randomized Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026001116
Enrollment
Unknown
Registered
2026-04-28
Start date
2024-01-08
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adolescent Depression

Interventions

Study group:Standardized psychological counseling (same as control group) plus Sini Powder combined with Xiaoxianxiong Decoction, once daily for 8 weeks
Control group:Standardized psychological counseling including cognitive behavioral intervention (45 min/session) and family support guidance (30 min/session), once a week for 8 weeks.

Sponsors

The Third Hospital of Mianyang, Mianyang, Sichuan Province, China
Lead Sponsor

Eligibility

Sex/Gender
All
Age
12 Years to 18 Years

Inclusion criteria

Inclusion criteria: 1) Meet the diagnostic criteria for depression in the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5)(Guha M et al, 2014); 2) TCM syndrome differentiation conforms to the syndrome of liver qi stagnation transforming into heat and phlegm-heat stagnation in the chest, with main symptoms including low mood, irritability and easy anger, chest tightness and stuffiness; secondary symptoms including bitter mouth and dry throat, poor appetite, insomnia and dreaminess, red tongue with yellow and greasy coating, stringy and rapid pulse(Ye W et al, 2025); Clinical Application Guidelines for Chinese Patent Medicines in the Treatment of Depressive Disorder (Standardization Project Team of *Guidelines for Clinical Application of Chinese Patent Medicines in the Treatment of Dominant Diseases*, 2023)3) Aged 12-18 years; 4) CDRS-R score =20 points at baseline (indicating moderate depressive severity); 5) No use of antidepressant drugs, TCM decoctions, or other mental intervention measures in the past 1 month; 6) Voluntarily participate in the study and cooperate with follow-up.

Exclusion criteria

Exclusion criteria: 1) Complicated with other mental diseases such as schizophrenia, bipolar affective disorder, and autism spectrum disorder; 2) Complicated with severe liver, kidney, heart, or other organ dysfunction; 3) Complicated with immune system diseases, endocrine diseases, or malignant tumors; 4) Allergic to the Chinese medicinal materials used in the study; 5) Poor compliance, unable to complete the intervention course or follow-up; 6) With a history of drug abuse or alcoholism.

Design outcomes

Primary

MeasureTime frame
Children's Depression Rating Scale-Revised (CDRS-R) score;TCM syndrome score;

Secondary

MeasureTime frame
Pediatric Quality of Life Inventory (PedsQL) score;Clinical effective rate ;Adverse events;

Countries

China

Contacts

Public ContactRuiyu Lin

The Third Hospital of Mianyang, Mianyang, Sichuan Province, China

50982453@qq.com13778027734

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Jun 11, 2026